Technical Narrative Response Template.docx
DOCX document 22 KB Posted
- Attached to
- Advanced Dermal Regeneration Substitutes for Treatment of Severe Burns and Complex Traumatic Injuries
- Solicitation number
- BARDA-CBRN-07282026
About this file
This is a Technical Narrative Response Template for a Sources Sought Notice issued by the Biomedical Advanced Research and Development Authority (BARDA), an office within the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response. The notice, numbered BARDA-CBRN-07282026, seeks information on innovative dermal regeneration technologies capable of treating large-area skin loss from thermal burns or traumatic injuries in mass casualty scenarios. Respondents must provide company information, product details including FDA product codes, and technical narratives addressing dermal regeneration capability, infection control mechanisms, use-case flexibility, and manufacturing scalability—each section limited to specific word counts ranging from 100 to 500 words. The template requires documentation of material sourcing, current production and surge capacity, storage requirements including temperature and shelf life specifications, clinical evidence, FDA regulatory status (510(k) clearance, PMA approval, or investigational stage), and prior military or emergency use experience.
The template further mandates disclosure of product composition type (fully synthetic, biosynthetic, acellular, or cellular), indication for specific patient populations (adult, pediatric, geriatric, or all), applicable wound types, usability in austere environments, application time per patient, deployment timeline from order to delivery, and pre-positioned inventory locations. Respondents must detail ambient storage capability, cold chain requirements, mass casualty surge use capability, treatable surface area per unit, distribution channels, and packaging configurations. Supporting documentation attachments required include clinical data, regulatory documentation, product instructions for use (IFU), manufacturing overview, and other relevant evidence. This is a pre-solicitation notice intended solely to assess the current state of commercially available or near-commercial technologies; no contract award, pricing information, or response deadline is specified in this template document.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| BARDA-CBRN-07282026.pdf |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Sources Sought Notice Title: Advanced Dermal Regeneration Substitutes for Treatment of Severe Burns and Complex Traumatic Injuries Special Notice No.: BARDA-CBRN-07282026
Summary of Technical Representations Offeror Information
· Company Name: _______________________________________
· Point of Contact: _______________________________________
· Email: ________________________________________________
· Phone: _______________________________________________
· Product Name: _________________________________________
· FDA Product Code: _____________________________________
1. Dermal Regeneration Capability
1.1 Describe the mechanism by which the product supports the formation of a vascularized neodermis and for which wound types has the product been evaluated. Include any relevant top-line preclinical or clinical evidence.
(no more than 500 words)
1.2 How does your product integrate with host tissue, and what is the typical timeline for epithelialization?
(no more than 500 words)
2. Infection Control and Barrier Function
2.1 Does the product incorporate antimicrobial agents or biofilm-resistant features? If so, describe the mechanism and duration of effectiveness.
(no more than 500 words)
2.2 Provide information demonstrating infection rates associated with the product compared to standard of care.
(no more than 500 words)
3. Use-Case Flexibility
3.1 Preparation Requirements
☐ Ready-to-use ☐ Minimal prep ☐ Requires preparation (no more than 100 words)
3.2 Describe special handling requirements or additional materials needed for application.
(no more than 500 words)
4. Scalability and Manufacturing
4.1 Material Dependency
☐ Synthetic ☐ Animal-derived ☐ Human-derived ☐ Biosynthetic Explain sourcing and supply chain considerations (no more than 100 words):
4.2 Current Production Capacity Supporting Annual Sales (units/month):
4.3 Surge/Maximum Capacity:
4.4 Current Inventory On-Hand:
4.5 Annual Inventory Surplus (Average of the Past 3 Years):
5. Ease of Use in Diverse Settings
5.1 Usability in Austere Environments
☐ Yes ☐ No Details (no more than 100 words):
5.2 Required Expertise Level
☐ Basic ☐ Moderate ☐ Specialized (surgical) Details:
5.3 Application Time (per patient):
5.4 How does the product integrate into existing burn care workflows and standards of care?
(no more than 500 words)
6. Clinical and Regulatory Maturity
6.1 Clinical Evidence Summary
(no more than 500 words)
6.2 FDA Regulatory Status
☐ Cleared (510k) ☐ Approved (PMA) ☐ Investigational
6.3 Regulatory Pathway / Timeline (if applicable)
(no more than 500 words)
6.4 Prior Emergency / Military Use (e.g., prior or current grants, contracts, partnerships).
(no more than 500 words)
6.5 Describe the current or anticipated reimbursement pathway.
(no more than 500 words)
7. Composition of Product
7.1 Product Type
☐ Fully Synthetic ☐ Biosynthetic ☐ Acellular ☐ Cellular
7.2 Describe the material components and their functional roles in wound healing.
(no more than 500 words)
7.3 If biosynthetic or biologic components are used, describe sourcing, processing, and associated risks.
(no more than 500 words)
7.4 Are there any biocompatibility / immunogenicity considerations?
(no more than 100 words)
8. Storage Requirements
8.1 Storage Conditions (Temp/Environment)
(no more than 100 words)
8.2 Ambient Storage Capability
☐ Yes ☐ No Details (no more than 100 words):
8.3 Shelf Life:
8.4 Cold Chain Requirements
☐ Yes ☐ No Details (no more than 100 words):
8.5 Stability Under Excursions
(no more than 500 words)
9. Indicated Population
9.1 Patient Populations
☐ Adult ☐ Pediatric ☐ Geriatric ☐ All
9.2 Wound Types / Indications
(no more than 500 words)
9.3 Anatomical Limitations
(no more than 500 words)
10. Scalability of Treatment
10.1 Mass Casualty / Surge Use Capability
☐ Yes ☐ No Details (no more than 100 words):
10.2 Treatable Surface Area per Unit
(no more than 100 words)
10.3 Number of Applications Required
(no more than 100 words)
11. Rapid Deployment and Distribution
11.1 Deployment Timeline (order-to-delivery)
(no more than 100 words)
11.2 Pre-positioned Inventory
☐ Yes ☐ No Locations:
11.3 What distribution channels are currently in place (e.g., direct shipment, distributors, government partnerships)?
(no more than 500 words)
11.4 What are the packaging configurations (e.g., individual units, bulk kits) and how do they support rapid deployment?
(no more than 500 words)
12. Supporting Documentation and Evidence Attachments ☐ Clinical Data ☐ Regulatory Documentation ☐ Product IFU ☐ Manufacturing Overview ☐ Other:
File details come from the government source that posted it. Updated .